APOLLOMICS INC. news, videos and press releases
For more news please use our advanced search feature.
APOLLOMICS INC. - More news...
APOLLOMICS INC. - More news...
- Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
- Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
- Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
- Apollomics Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
- Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
- Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
- Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
- Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
- Apollomics to Present at the Canaccord Genuity 44th Annual Growth Conference
- Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
- Apollomics Announces Updated Strategic Focus and Leadership Team Changes
- Apollomics Announces Vebreltinib Data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Apollomics Announces Presentation at the 2024 BIO International Convention
- Apollomics Announces Private Placement Financing and Addition to Board of Directors
- Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
- Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- Apollomics Announces Poster Presentations of Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
- Apollomics to Announce Full Year 2023 Financial Results and Host Conference Call on March 28, 2024
- Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
- Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
- Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference
- Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
- Apollomics to Present at the 2024 Biotech Showcase
- Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation
- Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
- Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
- Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
